<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708110</url>
  </required_header>
  <id_info>
    <org_study_id>111521</org_study_id>
    <nct_id>NCT00708110</nct_id>
  </id_info>
  <brief_title>Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults</brief_title>
  <official_title>A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults (ING111521)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <brief_summary>
    <textblock>
      GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV
      infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging,
      placebo-controlled 'proof of concept' study is to be conducted to compare antiviral effect,
      safety, tolerability, and pharmacokinetics of GSK1349572 monotherapy versus placebo over 10
      days in ART-naïve and experienced, but integrase inhibitor naïve (meaning never having had an
      integrase inhibitor) HIV-1 infected adults who are not currently receiving antiretroviral
      therapy. This study consists of a screening visit, a treatment period and a follow-up
      evaluation. Thirty subjects will be randomized to receive one of three doses of GSK1349572 or
      placebo q24h over 10 days. Antiviral effect measures include viral load and CD4 cell count.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11</measure>
    <time_frame>Baseline (Day 1) and Day 11</time_frame>
    <description>Change from Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) was calculated as the Day 11 value minus the Baseline value. Blood samples for the measurement of HIV-1 RNA levels were obtained throughout the treatment period (Day 1 to Day 11).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) and Over 24 Hours (AUC[0-24]) of GSK1349572 Following Dose Administration on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to24 hours. Blood samples for pharmacokinetic (PK) analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) and Concentration at 24 Hours Post Dose (C24) of GSK1349572 Following Dose Administration on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration, and C24 is defined as the concentration at 24 hours post dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, Cmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) and Absorption Lag Time (Tlag) of GSK1349572 Following Dose Administration on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>tmax is defined as the time to the maximum obsevered plasma concentration. Absorption lag time is defined as the time taken for a drug to appear in the systemic circulation following administration. tlag was estimated based on PK sampling times of 0 (pre-dose), 0.5, 1, 1.5, 2 3, 4, 6, 8, 12, and 24 hours post-dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of GSK1349572 Following Dose Administration on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK1349572 Following the Last Repeat Administration on Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-tau) is defined as the area under the concentration-time curve over the dosing interval. Blood samples for PK analysis of GSK1349572 were obtained on Day 10at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose Concentration (C0), Concentration at the End of the Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin), and Maximum Obsevered Plasma Concentration (Cmax) of GSK1349572 Following the Last Repeat Administration</measure>
    <time_frame>Day 10</time_frame>
    <description>C0 is defined as the pre-dose concentration. Ctau is defined as the concentration at the end of the dosing interval. Cmin is defined as the minimum observed concentration during one dosing interval. Cmax is defined as the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the Maximum Observed Concentration (Tmax) of GSK1349572 Following the Last Repeat Administration on Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>tmax is defined as the time to the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of GSK1349572 Following the Last Repeat Administration on Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Non-serious Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up (average of 3 study weeks)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Received the Indicated Concomitant Medications During the Study Period</measure>
    <time_frame>From Baseline (Day 1) until Follow-up (average of 3 study weeks)</time_frame>
    <description>Concomitant medications received during the study period are presented by generic term. Only those concomitant medications that were received by at least two participants are presented. &quot;Multiple ingredient&quot; is the term used in the statistical package for items that contain more than one active ingredient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Blood Pressure at Days 1, 4, 7, and 10</measure>
    <time_frame>Baseline and Days 1, 4, 7, and 10</time_frame>
    <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Change in the mean blood pressure from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Heart Rate at Days 1, 4, 7, and 10</measure>
    <time_frame>Baseline and Days 1, 4, 7, and 10</time_frame>
    <description>Heart rate is the measure of heart beats per minute (bpm). Change in the mean heart rate from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Screening; Days 1, 7, 10, 11; and Follow-up (up to Study Day 21)</time_frame>
    <description>A 12-lead electrocardiogram (ECG) was performed by qualified personnel at the site after the participant had rested for at least 5 minutes in a semi-recumbent or supine position. If a QTc measurement of &gt;=500 milliseconds (msec) was noted on a scheduled or unscheduled ECG, two additional ECGs were to be obtained within 5 minutes to confirm the abnormality. The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) ECG findings are presented here. The site determined if an ECG finding is significant or not. ECGs were obtained at Screening, Day 1 (pre-dose [twice] and then 1.0, 1.5, and 2.0 hours [hrs] post dose), Day 4 (pre-dose), Day 7 (pre-dose), Day 10 (pre-dose and then 1.0, 1.5, and 2.0 hrs post dose), Day 11 (prior to the 24 hr PK sample [pre lab]), and Follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Grade 3 and Grade 4 Laboratory Abnormalities</measure>
    <time_frame>Screening; Days 1, 3, 7, and 10; and Follow-up (up to Study Day 21)</time_frame>
    <description>Clinical laboratory toxicities were graded according to the National Institutes of Allergy and Infectious Diseases (NIAID), Division of Acquired Immunodeficiency Syndrome (DAIDS). Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented only for Grade 3 and Grade 4 laboratory abnormalities. Clinical laboratory abnormalities included: increased glucose, lipase, decreased platelets, and triglycerides.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</measure>
    <time_frame>Baseline and Day 11</time_frame>
    <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</measure>
    <time_frame>Baseline and Day 11</time_frame>
    <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA Rate of Decline Over 10 Days</measure>
    <time_frame>Day 1 to Day 11</time_frame>
    <description>The rate of decline of plasma HIV-1 RNA levels from Day 1 to Day 11 was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL</measure>
    <time_frame>Day 11</time_frame>
    <description>The number of participants who achieved plasma HIV-1 RNA levels &lt;400 copies/mL and &lt;50 copies/mL through Day 11 was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</measure>
    <time_frame>Baseline and Follow-up period (Days 11 to 21)</time_frame>
    <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</measure>
    <time_frame>Baseline and Follow-up period (Days 11 to 21)</time_frame>
    <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Day 11</measure>
    <time_frame>Baseline and Day 11</time_frame>
    <description>Median change from Baseline in CD4+ cell count was calculated as the Day 11 value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Emergence of Drug Resistance Mutations</measure>
    <time_frame>Baseline and Day 11</time_frame>
    <description>The number of participants with the emergence (from Baseline) of drug resistance mutations at Day 11 was measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1349572</intervention_name>
    <description>GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a tablet with no drug in it.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;/18 and &lt;/ 65 years of age.

          -  A female subject is eligible to participate if she is of non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation, hysterectomy or
             bilateral oophorectomy; or postmenopausal defined as 12 months of spontaneous
             amenorrhea [in questionable cases a blood sample with simultaneous follicle
             stimulating hormone (FSH) &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) is
             confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal
             status is in doubt will be required to use one of the contraception methods in Section
             8.1 if they wish to continue their HRT during the study. Otherwise, they must
             discontinue HRT to allow confirmation of post-menopausal status prior to study
             enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the
             cessation of therapy and the blood draw; this interval depends on the type and dosage
             of HRT. Following confirmation of their post-menopausal status, they can resume use of
             HRT during the study without use of a contraceptive method.

          -  Male subjects must agree to use one of the contraception methods listed in Section
             8.1. This criterion must be followed from the time of the first dose of study
             medication until 14 days after the last dose of study drug.

          -  CD4+ cell count &gt;/ 100 cells/mm3.

          -  Documented HIV-1 infection and a screening plasma HIV-1 RNA &gt;/ 5000 copies/mL.

          -  No current antiretroviral therapy and have not received any in the 12 weeks prior to
             first dose.

          -  Capable of giving written informed consent, which includes compliance

        Exclusion Criteria:

          -  The subject has a positive pre-study drug screen. Drugs that will be screened for
             include amphetamines, barbiturates, cocaine, and PCP.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation. In addition, if heparin is used
             during PK sampling, subjects with a history of sensitivity to heparin or
             heparin-induced thrombocytopenia should not be enrolled.

          -  Prior treatment with an integrase inhibitor (&gt; 1 dose).

          -  Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 30 days
             of study drug administration or anticipated need for such treatment within the study.

          -  Treatment with immunomodulating agents (such as systemic corticosteroids,
             interleukins, interferons) or any agent with known anti-HIV activity (such as
             hydroxyurea or foscarnet) within 30 days of study drug administration

          -  Treatment with any vaccine within 30 days prior to receiving study medication.

          -  Use of multivitamins or antacids within 24 hours prior to the first dose of
             investigational product.

          -  History of regular alcohol consumption within 6 months of the screening visit defined
             as: an average weekly intake of &gt;14 drinks/week for men or &gt;7 drinks/week for women.
             One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces
             (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Pregnant females as determined by positive urine/serum hCG test at screening or prior
             to dosing.

          -  Lactating females.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Any condition (including alcohol or drug abuse) which, in the opinion of the
             investigator, could interfere with the subject's ability to comply with the dosing
             schedule and protocol evaluations or which might compromise the safety of the subject.

          -  An active Center for Disease Control and Prevention (CDC) Category C disease [see
             Appendix 1], except cutaneous Kaposi's sarcoma not requiring systemic therapy during
             the trial.

          -  History of clinically relevant pancreatitis or hepatitis within the previous 6 months.

          -  Subjects with a pre-existing condition interfering with normal gastrointestinal
             anatomy or motility, hepatic and/or renal function, that could interfere with the
             absorption, metabolism, and/or excretion of the study drugs.

          -  Has a positive screening Hepatitis B surface antigen; positive screening hepatitis C
             virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) on subsequent testing.
             If the hepatitis C antibody is positive but the HCV RNA is undetectable, the subject
             may be included in the study.

          -  Inadequate renal function at Screening, defined as either a serum creatinine &gt;1.5
             mg/dL or a calculated creatinine clearance (CrCl) ≤ 50 mL/min. A single repeat serum
             creatinine is allowed to determine eligibility.

          -  Any acute laboratory abnormality at screen which, in the opinion of the investigator,
             should preclude the subject's participation in the study of an investigational
             compound. Any grade 4 laboratory abnormality at screen, with the exception of CPK,
             will exclude a subject from study participation unless the investigator can provide a
             compelling explanation for the laboratory result(s) and has the assent of the sponsor.
             A single repeat is allowed for eligibility determination.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x times the
             upper limit of normal. A single repeat of ALT and/or AST is allowed for eligibility
             determination.

          -  Exclusion Criteria for Screening ECG (A single repeat is allowed for eligibility
             determination):
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.</citation>
    <PMID>21716073</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <results_first_submitted>August 22, 2013</results_first_submitted>
  <results_first_submitted_qc>August 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2013</results_first_posted>
  <disposition_first_submitted>July 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dose-ranging study</keyword>
  <keyword>phase IIa</keyword>
  <keyword>integrase inhibitor</keyword>
  <keyword>HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Integrase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="P2">
          <title>GSK1349572 2 mg QD</title>
          <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="P3">
          <title>GSK1349572 10 mg QD</title>
          <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="P4">
          <title>GSK1349572 50 mg QD</title>
          <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="B2">
          <title>GSK1349572 2 mg QD</title>
          <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="B3">
          <title>GSK1349572 10 mg QD</title>
          <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="B4">
          <title>GSK1349572 50 mg QD</title>
          <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="10.64"/>
                    <measurement group_id="B2" value="41.1" spread="10.47"/>
                    <measurement group_id="B3" value="39.9" spread="4.14"/>
                    <measurement group_id="B4" value="33.7" spread="10.45"/>
                    <measurement group_id="B5" value="38.4" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White – White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11</title>
        <description>Change from Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) was calculated as the Day 11 value minus the Baseline value. Blood samples for the measurement of HIV-1 RNA levels were obtained throughout the treatment period (Day 1 to Day 11).</description>
        <time_frame>Baseline (Day 1) and Day 11</time_frame>
        <population>Intent to Treat Exposed (ITT[E]) Population: all participants who met study criteria and were randomized into the study with documented evidence of having received at least one dose of randomized treatment and at least one post-baseline HIV-1 RNA measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11</title>
          <description>Change from Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) was calculated as the Day 11 value minus the Baseline value. Blood samples for the measurement of HIV-1 RNA levels were obtained throughout the treatment period (Day 1 to Day 11).</description>
          <population>Intent to Treat Exposed (ITT[E]) Population: all participants who met study criteria and were randomized into the study with documented evidence of having received at least one dose of randomized treatment and at least one post-baseline HIV-1 RNA measurement</population>
          <units>Log10 copies/milliliter (log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.26"/>
                    <measurement group_id="O2" value="-1.51" spread="0.58"/>
                    <measurement group_id="O3" value="-2.03" spread="0.49"/>
                    <measurement group_id="O4" value="-2.46" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>-1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.94</ci_lower_limit>
            <ci_upper_limit>-2.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</title>
        <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Day 11</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</title>
          <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT(E) Population</population>
          <units>Log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.50"/>
                    <measurement group_id="O2" value="-1.58" spread="0.55"/>
                    <measurement group_id="O3" value="-2.09" spread="0.49"/>
                    <measurement group_id="O4" value="-2.61" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</title>
        <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Day 11</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Plasma HIV-1 RNA to Nadir (Maximum Change) at Day 11</title>
          <description>Plasma HIV-1 RNA change from Baseline to the on-treatment nadir (maximum change) was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT(E) Population</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" lower_limit="-1.39" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-1.65" lower_limit="-2.34" upper_limit="-0.86"/>
                    <measurement group_id="O3" value="-1.99" lower_limit="-2.71" upper_limit="-1.43"/>
                    <measurement group_id="O4" value="-2.55" lower_limit="-3.28" upper_limit="-2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HIV-1 RNA Rate of Decline Over 10 Days</title>
        <description>The rate of decline of plasma HIV-1 RNA levels from Day 1 to Day 11 was measured.</description>
        <time_frame>Day 1 to Day 11</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV-1 RNA Rate of Decline Over 10 Days</title>
          <description>The rate of decline of plasma HIV-1 RNA levels from Day 1 to Day 11 was measured.</description>
          <population>ITT(E) Population</population>
          <units>Log10 copies/mL/day</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.01" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.16" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.20" lower_limit="-0.21" upper_limit="-0.18"/>
                    <measurement group_id="O4" value="-0.25" lower_limit="-0.27" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL</title>
        <description>The number of participants who achieved plasma HIV-1 RNA levels &lt;400 copies/mL and &lt;50 copies/mL through Day 11 was measured.</description>
        <time_frame>Day 11</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL</title>
          <description>The number of participants who achieved plasma HIV-1 RNA levels &lt;400 copies/mL and &lt;50 copies/mL through Day 11 was measured.</description>
          <population>ITT(E) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) and Over 24 Hours (AUC[0-24]) of GSK1349572 Following Dose Administration on Day 1</title>
        <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to24 hours. Blood samples for pharmacokinetic (PK) analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Summary (PKS) Population: participants (par.) with an evaluable profile of GSK1349572 on Day 10. Par. were excluded if they vomited within 2 hours of dosing on Day 10, missed more than one dose 2 days prior to Day 10, and took prohibited concomitant medication during the treatment period. No par. were analyzed in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) and Over 24 Hours (AUC[0-24]) of GSK1349572 Following Dose Administration on Day 1</title>
          <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to24 hours. Blood samples for pharmacokinetic (PK) analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>Pharmacokinetic Summary (PKS) Population: participants (par.) with an evaluable profile of GSK1349572 on Day 10. Par. were excluded if they vomited within 2 hours of dosing on Day 10, missed more than one dose 2 days prior to Day 10, and took prohibited concomitant medication during the treatment period. No par. were analyzed in the placebo group.</population>
          <units>Micrograms*hour per milliliter (µg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.63" spread="39"/>
                    <measurement group_id="O3" value="10.1" spread="26"/>
                    <measurement group_id="O4" value="40.5" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.05" spread="33"/>
                    <measurement group_id="O3" value="7.41" spread="27"/>
                    <measurement group_id="O4" value="30.34" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) and Concentration at 24 Hours Post Dose (C24) of GSK1349572 Following Dose Administration on Day 1</title>
        <description>Cmax is defined as the maximum observed plasma concentration, and C24 is defined as the concentration at 24 hours post dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, Cmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
        <time_frame>Day 1</time_frame>
        <population>PKS Population. No participants were analyzed in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) and Concentration at 24 Hours Post Dose (C24) of GSK1349572 Following Dose Administration on Day 1</title>
          <description>Cmax is defined as the maximum observed plasma concentration, and C24 is defined as the concentration at 24 hours post dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, Cmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
          <population>PKS Population. No participants were analyzed in the placebo group.</population>
          <units>Micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.18" spread="35"/>
                    <measurement group_id="O3" value="0.57" spread="28"/>
                    <measurement group_id="O4" value="2.46" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.03" spread="49"/>
                    <measurement group_id="O3" value="0.15" spread="30"/>
                    <measurement group_id="O4" value="0.59" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) and Absorption Lag Time (Tlag) of GSK1349572 Following Dose Administration on Day 1</title>
        <description>tmax is defined as the time to the maximum obsevered plasma concentration. Absorption lag time is defined as the time taken for a drug to appear in the systemic circulation following administration. tlag was estimated based on PK sampling times of 0 (pre-dose), 0.5, 1, 1.5, 2 3, 4, 6, 8, 12, and 24 hours post-dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
        <time_frame>Day 1</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) and Absorption Lag Time (Tlag) of GSK1349572 Following Dose Administration on Day 1</title>
          <description>tmax is defined as the time to the maximum obsevered plasma concentration. Absorption lag time is defined as the time taken for a drug to appear in the systemic circulation following administration. tlag was estimated based on PK sampling times of 0 (pre-dose), 0.5, 1, 1.5, 2 3, 4, 6, 8, 12, and 24 hours post-dose. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.50" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.02" upper_limit="6.00"/>
                    <measurement group_id="O4" value="2.09" lower_limit="1.00" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tlag</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) of GSK1349572 Following Dose Administration on Day 1</title>
        <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 1</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of GSK1349572 Following Dose Administration on Day 1</title>
          <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.7" spread="30"/>
                    <measurement group_id="O3" value="11.8" spread="22"/>
                    <measurement group_id="O4" value="11.2" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 1</title>
        <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 1</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 1</title>
          <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 1at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>Liters per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.76" spread="39"/>
                    <measurement group_id="O3" value="0.99" spread="26"/>
                    <measurement group_id="O4" value="1.23" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
        <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-tau) is defined as the area under the concentration-time curve over the dosing interval. Blood samples for PK analysis of GSK1349572 were obtained on Day 10at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 10</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
          <description>AUC is defined as the area under the GSK1349572 concentration-time curve as a measure of drug exposure. AUC(0-tau) is defined as the area under the concentration-time curve over the dosing interval. Blood samples for PK analysis of GSK1349572 were obtained on Day 10at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>µg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.56" spread="29"/>
                    <measurement group_id="O3" value="10.13" spread="20"/>
                    <measurement group_id="O4" value="43.39" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose Concentration (C0), Concentration at the End of the Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin), and Maximum Obsevered Plasma Concentration (Cmax) of GSK1349572 Following the Last Repeat Administration</title>
        <description>C0 is defined as the pre-dose concentration. Ctau is defined as the concentration at the end of the dosing interval. Cmin is defined as the minimum observed concentration during one dosing interval. Cmax is defined as the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 10</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Concentration (C0), Concentration at the End of the Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin), and Maximum Obsevered Plasma Concentration (Cmax) of GSK1349572 Following the Last Repeat Administration</title>
          <description>C0 is defined as the pre-dose concentration. Ctau is defined as the concentration at the end of the dosing interval. Cmin is defined as the minimum observed concentration during one dosing interval. Cmax is defined as the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.04" spread="51"/>
                    <measurement group_id="O3" value="0.20" spread="28"/>
                    <measurement group_id="O4" value="0.82" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.04" spread="50"/>
                    <measurement group_id="O3" value="0.19" spread="25"/>
                    <measurement group_id="O4" value="0.83" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.04" spread="51"/>
                    <measurement group_id="O3" value="0.19" spread="26"/>
                    <measurement group_id="O4" value="0.81" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.22" spread="25"/>
                    <measurement group_id="O3" value="0.80" spread="23"/>
                    <measurement group_id="O4" value="3.34" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to the Maximum Observed Concentration (Tmax) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
        <description>tmax is defined as the time to the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
        <time_frame>Day 10</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Maximum Observed Concentration (Tmax) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
          <description>tmax is defined as the time to the maximum obsevered plasma concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration. From the plasma concentration-time curve, tmax was determined by standard non-compartmental analysis using WinNonlin Pro 4.1 or higher.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.00" lower_limit="0.42" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.48" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.97" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
        <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 10</time_frame>
        <population>PKS Population. No participants were analysed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of GSK1349572 Following the Last Repeat Administration on Day 10</title>
          <description>The terminal half-life (t1/2) of GSK1349572 is defined as the time required for the plasma concentration of GSK1349572 to reach half of its original concentration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analysed for the placebo group.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11.13" spread="24"/>
                    <measurement group_id="O3" value="11.64" spread="21"/>
                    <measurement group_id="O4" value="11.95" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 10</title>
        <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
        <time_frame>Day 10</time_frame>
        <population>PKS Population. No participants were analyzed for the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of GSK1349572 Following Dose Administration on Day 10</title>
          <description>The CL/F is defined as the apparent total clearance of the drug from plasma after oral administration. Blood samples for PK analysis of GSK1349572 were obtained on Day 10 at pre-dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post GSK1349572 dose administration.</description>
          <population>PKS Population. No participants were analyzed for the placebo group.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.78" spread="29"/>
                    <measurement group_id="O3" value="0.99" spread="20"/>
                    <measurement group_id="O4" value="1.15" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Non-serious Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
        <time_frame>From Baseline (Day 1) until Follow-up (average of 3 study weeks)</time_frame>
        <population>Safety Population: all participants who were randomized into the study with documented evidence of having received at least one dose of randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-serious Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
          <population>Safety Population: all participants who were randomized into the study with documented evidence of having received at least one dose of randomized treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Received the Indicated Concomitant Medications During the Study Period</title>
        <description>Concomitant medications received during the study period are presented by generic term. Only those concomitant medications that were received by at least two participants are presented. “Multiple ingredient” is the term used in the statistical package for items that contain more than one active ingredient.</description>
        <time_frame>From Baseline (Day 1) until Follow-up (average of 3 study weeks)</time_frame>
        <population>Safety Population. Only those participants who received a concomitant medication were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received the Indicated Concomitant Medications During the Study Period</title>
          <description>Concomitant medications received during the study period are presented by generic term. Only those concomitant medications that were received by at least two participants are presented. “Multiple ingredient” is the term used in the statistical package for items that contain more than one active ingredient.</description>
          <population>Safety Population. Only those participants who received a concomitant medication were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Multiple ingredients (combination product)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bupropion hydrochloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Escitalopram oxalate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetylsalicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyanocobalamin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fish oil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loratadine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ranitidine hydrochloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trazodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valacyclovir hydrochloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitamin B substances (not otherwise specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zolpidem tartrate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Blood Pressure at Days 1, 4, 7, and 10</title>
        <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Change in the mean blood pressure from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
        <time_frame>Baseline and Days 1, 4, 7, and 10</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Blood Pressure at Days 1, 4, 7, and 10</title>
          <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Change in the mean blood pressure from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
          <population>Safety Population</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.93" spread="6.051"/>
                    <measurement group_id="O2" value="-1.11" spread="6.348"/>
                    <measurement group_id="O3" value="-2.17" spread="5.551"/>
                    <measurement group_id="O4" value="3.10" spread="12.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 4, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="10.221"/>
                    <measurement group_id="O2" value="1.78" spread="4.874"/>
                    <measurement group_id="O3" value="1.72" spread="11.880"/>
                    <measurement group_id="O4" value="-7.60" spread="10.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="12.188"/>
                    <measurement group_id="O2" value="-0.56" spread="10.227"/>
                    <measurement group_id="O3" value="2.28" spread="8.544"/>
                    <measurement group_id="O4" value="-2.90" spread="9.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 10, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="11.419"/>
                    <measurement group_id="O2" value="2.89" spread="10.836"/>
                    <measurement group_id="O3" value="4.94" spread="6.640"/>
                    <measurement group_id="O4" value="-6.40" spread="11.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 10, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="11.193"/>
                    <measurement group_id="O2" value="2.67" spread="9.311"/>
                    <measurement group_id="O3" value="3.50" spread="10.974"/>
                    <measurement group_id="O4" value="-6.40" spread="10.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="5.321"/>
                    <measurement group_id="O2" value="1.39" spread="4.060"/>
                    <measurement group_id="O3" value="2.33" spread="4.183"/>
                    <measurement group_id="O4" value="-2.70" spread="8.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 4, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="6.658"/>
                    <measurement group_id="O2" value="1.72" spread="7.480"/>
                    <measurement group_id="O3" value="-0.67" spread="7.036"/>
                    <measurement group_id="O4" value="-3.20" spread="4.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="7.262"/>
                    <measurement group_id="O2" value="1.61" spread="8.543"/>
                    <measurement group_id="O3" value="1.33" spread="6.708"/>
                    <measurement group_id="O4" value="-2.40" spread="6.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 10, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="8.696"/>
                    <measurement group_id="O2" value="0.17" spread="4.690"/>
                    <measurement group_id="O3" value="4.11" spread="6.314"/>
                    <measurement group_id="O4" value="-7.00" spread="7.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 10, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="10.912"/>
                    <measurement group_id="O2" value="0.83" spread="8.775"/>
                    <measurement group_id="O3" value="6.00" spread="9.131"/>
                    <measurement group_id="O4" value="-4.90" spread="8.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Heart Rate at Days 1, 4, 7, and 10</title>
        <description>Heart rate is the measure of heart beats per minute (bpm). Change in the mean heart rate from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
        <time_frame>Baseline and Days 1, 4, 7, and 10</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Heart Rate at Days 1, 4, 7, and 10</title>
          <description>Heart rate is the measure of heart beats per minute (bpm). Change in the mean heart rate from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented for change from Baseline at Day 1 (2 hours post dose [hrs]), Day 4 (1 hr pre-dose), Day 7 (1 hr pre-dose), and Day 10 (1 hr pre-dose and 2 hrs post dose).</description>
          <population>Safety Population</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.71" spread="6.861"/>
                    <measurement group_id="O2" value="-7.67" spread="6.461"/>
                    <measurement group_id="O3" value="-2.83" spread="5.734"/>
                    <measurement group_id="O4" value="-6.85" spread="5.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="11.133"/>
                    <measurement group_id="O2" value="-3.22" spread="6.610"/>
                    <measurement group_id="O3" value="6.50" spread="9.434"/>
                    <measurement group_id="O4" value="2.95" spread="12.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="10.984"/>
                    <measurement group_id="O2" value="0.67" spread="8.047"/>
                    <measurement group_id="O3" value="3.72" spread="8.511"/>
                    <measurement group_id="O4" value="-2.85" spread="9.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1 hr pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="16.230"/>
                    <measurement group_id="O2" value="0.56" spread="9.547"/>
                    <measurement group_id="O3" value="3.83" spread="8.162"/>
                    <measurement group_id="O4" value="-0.95" spread="8.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 2 hrs post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="14.351"/>
                    <measurement group_id="O2" value="0.44" spread="13.907"/>
                    <measurement group_id="O3" value="-3.72" spread="8.635"/>
                    <measurement group_id="O4" value="-7.05" spread="7.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>A 12-lead electrocardiogram (ECG) was performed by qualified personnel at the site after the participant had rested for at least 5 minutes in a semi-recumbent or supine position. If a QTc measurement of &gt;=500 milliseconds (msec) was noted on a scheduled or unscheduled ECG, two additional ECGs were to be obtained within 5 minutes to confirm the abnormality. The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) ECG findings are presented here. The site determined if an ECG finding is significant or not. ECGs were obtained at Screening, Day 1 (pre-dose [twice] and then 1.0, 1.5, and 2.0 hours [hrs] post dose), Day 4 (pre-dose), Day 7 (pre-dose), Day 10 (pre-dose and then 1.0, 1.5, and 2.0 hrs post dose), Day 11 (prior to the 24 hr PK sample [pre lab]), and Follow-up.</description>
        <time_frame>Screening; Days 1, 7, 10, 11; and Follow-up (up to Study Day 21)</time_frame>
        <population>Safety Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>A 12-lead electrocardiogram (ECG) was performed by qualified personnel at the site after the participant had rested for at least 5 minutes in a semi-recumbent or supine position. If a QTc measurement of &gt;=500 milliseconds (msec) was noted on a scheduled or unscheduled ECG, two additional ECGs were to be obtained within 5 minutes to confirm the abnormality. The number of participants with abnormal clinically significant (CS) and not clinically significant (NCS) ECG findings are presented here. The site determined if an ECG finding is significant or not. ECGs were obtained at Screening, Day 1 (pre-dose [twice] and then 1.0, 1.5, and 2.0 hours [hrs] post dose), Day 4 (pre-dose), Day 7 (pre-dose), Day 10 (pre-dose and then 1.0, 1.5, and 2.0 hrs post dose), Day 11 (prior to the 24 hr PK sample [pre lab]), and Follow-up.</description>
          <population>Safety Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 1, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 1, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 1, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 2, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 2, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose 2, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hr post dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hr post dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hr post dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hrs post dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hrs post dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hrs post dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hrs post dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hrs post dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hrs post dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, pre-dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, pre-dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, pre-dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose, Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, pre-dose 1, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, pre-dose 1, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, pre-dose 1, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1 hr post dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1 hr post dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1 hr post dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1.5 hrs post dose, Normal, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1.5 hrs post dose, NCS, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 1.5 hrs post dose, CS, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 2 hrs post dose, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 2 hrs post dose, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 2 hrs post dose, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, pre lab, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, pre lab, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, pre lab, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, Normal, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, CS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, NCS, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Grade 3 and Grade 4 Laboratory Abnormalities</title>
        <description>Clinical laboratory toxicities were graded according to the National Institutes of Allergy and Infectious Diseases (NIAID), Division of Acquired Immunodeficiency Syndrome (DAIDS). Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented only for Grade 3 and Grade 4 laboratory abnormalities. Clinical laboratory abnormalities included: increased glucose, lipase, decreased platelets, and triglycerides.</description>
        <time_frame>Screening; Days 1, 3, 7, and 10; and Follow-up (up to Study Day 21)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Grade 3 and Grade 4 Laboratory Abnormalities</title>
          <description>Clinical laboratory toxicities were graded according to the National Institutes of Allergy and Infectious Diseases (NIAID), Division of Acquired Immunodeficiency Syndrome (DAIDS). Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented only for Grade 3 and Grade 4 laboratory abnormalities. Clinical laboratory abnormalities included: increased glucose, lipase, decreased platelets, and triglycerides.</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased glucose, Screening, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Glucose, Day 7, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Day 10, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased platelets, Day 1, n=6, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased platelets, Day 3, n=6, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased platelets, follow-up, n=7, 9, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, Day 7, n=7, 9, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</title>
        <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
        <time_frame>Baseline and Follow-up period (Days 11 to 21)</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</title>
          <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
          <population>ITT(E) Population</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.069" lower_limit="-1.39" upper_limit="0.22"/>
                    <measurement group_id="O2" value="-0.169" lower_limit="-0.92" upper_limit="0.54"/>
                    <measurement group_id="O3" value="-0.150" lower_limit="-0.61" upper_limit="0.34"/>
                    <measurement group_id="O4" value="-0.887" lower_limit="-1.96" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</title>
        <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
        <time_frame>Baseline and Follow-up period (Days 11 to 21)</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma HIV-1 RNA Levels During the Follow-up Period (Days 11 to 21)</title>
          <description>Change from Baseline in Plasma HIV-1 RNA levels was calculated as the value during the Follow-up period minus the Basline value.</description>
          <population>ITT(E) Population</population>
          <units>Log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.188" spread="0.5443"/>
                    <measurement group_id="O2" value="-0.149" spread="0.3931"/>
                    <measurement group_id="O3" value="-0.154" spread="0.3126"/>
                    <measurement group_id="O4" value="-0.899" spread="0.6997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Day 11</title>
        <description>Median change from Baseline in CD4+ cell count was calculated as the Day 11 value minus the Baseline value.</description>
        <time_frame>Baseline and Day 11</time_frame>
        <population>Per-Protocol Population: all participants included in the ITT(E) Population, excluding those who had at least one major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Day 11</title>
          <description>Median change from Baseline in CD4+ cell count was calculated as the Day 11 value minus the Baseline value.</description>
          <population>Per-Protocol Population: all participants included in the ITT(E) Population, excluding those who had at least one major protocol deviation</population>
          <units>Cells per cubic millimeter (cells/mm^3)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" lower_limit="-247" upper_limit="50"/>
                    <measurement group_id="O2" value="15.0" lower_limit="-286" upper_limit="222"/>
                    <measurement group_id="O3" value="106.0" lower_limit="-39" upper_limit="142"/>
                    <measurement group_id="O4" value="64.0" lower_limit="-155" upper_limit="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Emergence of Drug Resistance Mutations</title>
        <description>The number of participants with the emergence (from Baseline) of drug resistance mutations at Day 11 was measured.</description>
        <time_frame>Baseline and Day 11</time_frame>
        <population>ITT(E) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK1349572 2 mg QD</title>
            <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK1349572 10 mg QD</title>
            <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK1349572 50 mg QD</title>
            <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Emergence of Drug Resistance Mutations</title>
          <description>The number of participants with the emergence (from Baseline) of drug resistance mutations at Day 11 was measured.</description>
          <population>ITT(E) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from Baseline (Day 1) until Follow-up (average of 3 study weeks).</time_frame>
      <desc>SAEs and non-serious AEs were collected in the Safety Population, comprised of all participants who were randomized into the study with documented evidence of having received at least one dose of randomized treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets orally once daily (QD) for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="E2">
          <title>GSK1349572 2 mg QD</title>
          <description>Participants received GSK1349572 2 milligram (mg) tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="E3">
          <title>GSK1349572 10 mg QD</title>
          <description>Participants received GSK1349572 10 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
        <group group_id="E4">
          <title>GSK1349572 50 mg QD</title>
          <description>Participants received GSK1349572 50 mg tablets orally QD for 10 days and were followed for up to 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Daydreaming</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>ViiV Healthcare</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

